Abstract
The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and – Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
Keywords: VEGF, ranibizumab, lucentis, AMD, pegaptanib, VEGF-trap
Mini-Reviews in Medicinal Chemistry
Title: Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target
Volume: 9 Issue: 9
Author(s): A. Klettner and J. Roider
Affiliation:
Keywords: VEGF, ranibizumab, lucentis, AMD, pegaptanib, VEGF-trap
Abstract: The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and – Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
Export Options
About this article
Cite this article as:
Klettner A. and Roider J., Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target, Mini-Reviews in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/138955709788922665
DOI https://dx.doi.org/10.2174/138955709788922665 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Syncytin and GCMa: Key Regulators in Human Placental Physiology and in Pre-Eclampsia
Current Women`s Health Reviews Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress
Current Drug Targets Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Current Drug Targets Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Novel Nanotechnology Approaches for Targeted Cancer Therapy
Recent Patents on Nanomedicine Glutathione Transferases: Emerging Multidisciplinary Tools in Red and Green Biotechnology
Recent Patents on Biotechnology Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Molecular Targeted Magnetic Resonance Imaging of Human Colorectal Carcinoma (LoVo) Cells Using Novel Superparamagnetic Iron Oxide- Loaded Nanovesicles: In Vitro and in vivo Studies
Current Cancer Drug Targets Alternative Splicing and Tumor Progression
Current Genomics CYLD-Mediated Signaling and Diseases
Current Drug Targets Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued)